The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies

Vincent M. Perez¹, Joseph F. Kearney¹,² and Jen Jen Yeh¹,²,³*

¹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, ² Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, ³ Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

Pancreatic ductal adenocarcinoma (PDAC) is notorious for a dense fibrotic stroma that is interlaced with a collagen-based extracellular matrix (ECM) that plays an important role in tumor biology. Traditionally thought to only provide a physical barrier from host responses and systemic chemotherapy, new studies have demonstrated that the ECM maintains biomechanical and biochemical properties of the tumor microenvironment (TME) and restrains tumor growth. Recent studies have shown that the ECM augments tumor stiffness, interstitial fluid pressure, cell-to-cell junctions, and microvasculaity using a mix of biomechanical and biochemical signals to influence tumor fate for better or worse. In addition, PDAC tumors have been shown to use ECM-derived peptide fragments as a nutrient source in nutrient-poor conditions. While collagens are the most abundant proteins found in the ECM, several studies have identified growth factors, integrins, glycoproteins, and proteoglycans in the ECM. This review focuses on the dichotomous nature of the PDAC ECM, the types of collagens and other proteins found in the ECM, and therapeutic strategies targeting the PDAC ECM.

Keywords: pancreatic ductal adenocarcinoma, extracellular matrix, tumor microenvironment, proteome, cancer

INTRODUCTION

With a 5-year survival of 10%, pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer deaths in the United States and is projected to become the second leading cause of cancer deaths in the United States by 2030 (1, 2). Most patients have regional or distant spread at the time of diagnosis and are not eligible for a potentially curative operation (3). While advances have been made in the treatment of metastatic PDAC (4–6), most patients remain refractory to current regimens. Metastatic PDAC exhibits resistance to therapies like cytotoxic, radiation, and molecularly targeted therapies. A major factor thought to contribute to the treatment resistance of PDAC is its dense fibrotic stroma intertwined with the extracellular matrix (ECM), which together, provide a physical barrier of protection to the tumor cells and may also restrain tumor growth.
Research has shown that the ECM plays several roles beyond acting as a barrier for tumor cells. The deposition of abundant ECM proteins is common among solid tumors like PDAC and is known as a desmoplastic reaction (7). This tumor microenvironment (TME) exerts mechanical and biochemical properties on tumor cells, modulates interstitial fluid pressure (8, 9), and reduces blood vessel density within tumors (8). Although evidence has shown that the ECM may be tumor promoting (10), recent research has demonstrated that the stroma and ECM may restrain tumor growth (11, 12). In addition, tumor metastases, the primary cause of patient mortality, have less stroma than primary tumors (13, 14). A major regulator of the ECM are cancer-associated fibroblasts (CAFs), which dominate the TME in abundance (15).

CAFs are thought to arise predominantly from pancreatic stellate cells (PSCs) and bone-marrow derived mesenchymal stem cells. Their formation has been shown to be secondary to tumor signals (16). Several attempts have been made to target CAFs and the stroma; however, they have not been successful despite promising preclinical studies (9, 17). For example, genetic depletion of alpha-smooth muscle actin (αSMA) myofibroblasts in the stroma resulted in undifferentiated and invasive tumors with diminished survival (18). In the stromal PDAC patients, treatment with a pegylated recombinant human hyaluronidase (PEGPH20) combined with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) did not improve progression-free or overall survival (19). Trials using hedgehog (Hh) pathway inhibitors in combination with gemcitabine showed that the addition of Hh inhibitors was not superior to gemcitabine alone, and one study was prematurely terminated as patients treated with the Hh inhibitor did worse than the control arm (20–22). Despite these failures, targeting and modifying CAFs and the ECM continues to remain a topic of interest due to the substantial roles they play in tumor development, growth, and metastasis (23).

The cross-regulated and interacting networks of ECM proteins are fundamental to tumor homeostasis and tumorigenic activity like growth and metastasis (24–27) and must be further understood. This dynamic environment provides a reservoir for signaling molecules and prompts tumor cell activity via mechanical forces and biochemical signaling. This review covers the composition and general roles and regulation of the ECM in PDAC, key proteins in the ECM, and potential and ongoing targeting strategies.

**ECM OVERVIEW**

The ECM is a non-cellular component present in all tissue and provides the essential physical scaffolding, as well as biochemical and biomechanical cues to the surrounding cellular components. Consisting of water, proteins, and polysaccharides, the ECM composition adjusts based on the needs of the surrounding microenvironment. Most tissue require an ECM as an interstitial matrix in which the ECM is a 3-dimensional lattice supporting the surrounding cells of the stroma or a basement membrane in which the ECM is a matrix between epithelial and stromal layers of cells. Change in ECM architecture is a result of malignant cell transformation in many cancers, thus demonstrating the influence of biomechanical cues from the ECM (28, 29).

Tumor stroma has often been portrayed as a contributor to the development of the disease and tumor progression. However, several recent preclinical and clinical studies have shown that stroma-depletion can lead to a more aggressive disease (11, 18, 20, 30, 31). In patients, we and others have found that increased stroma correlates with improved survival and that stroma content at solid organ metastases is decreased (13, 14). Reduction of ECM through lysyl oxidase (LOX) inhibition in mouse models led to accelerated tumor growth (13).

Thus, the stroma and ECM play a dichotomous role in the TME as a tumor-promoting and tumor-inhibiting component, and selectively targeting the stroma and ECM may be the key. However, a more complete understanding of the stroma and the TME is necessary for this to succeed. The PDAC ECM is primarily composed of collagens, integrins, proteoglycans, glycoproteins, and proteases which all interact with tumor cells through a variety of mechanisms (32, 33) (Figure 1). Among these, collagens are the most abundant component.

**COLLAGENS**

The PDAC ECM contains combinations of type I, III, IV, V, and XV collagens (32, 34, 35). The interaction between collagen and the basement membrane proteins within the ECM plays an important role during malignant transformation (36, 37). Increased desmoplasia is thought to contribute to disruption of the basement membrane leading to increased exposure of PDAC cells to interstitial collagens and reduction of basement membrane collagens (33). In PDAC, lower collagen I and IV is associated with undifferentiated PDAC tumors (38). Basement membrane proteins are suggested to be tumor-inhibiting by restricting the epithelial-to-mesenchymal transition (EMT), whereas interstitial collagens may promote tumor growth through other mechanisms. Preclinical studies have shown that collagen may contribute to therapy resistance by modulating signaling pathways (39–41). In patients, studies have found that imaging characteristics may be reflective of stroma content and patient outcome (14, 42).

**Collagens I, III, IV, and V**

Collagen I is among the most abundant collagen in PDAC stroma and is generally suggested to be responsible for most of the desmoplastic reaction and has been associated with reduced survival in PDAC patients (43–45). However, when C-terminal prodomains of collagen I are cleaved by procollagen C-proteinase activity, collagen I may restrain tumor growth (46, 47). In addition, the presence of collagen I in the TME does not appear to inhibit T-cell infiltration (48), further suggesting the stroma has roles beyond a physical barrier. Collagen III is the second most abundant collagen present in the PDAC ECM (32).
Like collagen I, collagen III may suppress tumor growth when cleaved (32). In addition, the ratio of collagen III to collagen III peptide fragments may be predictive of improved patient survival (49). Collagen IV, a collagen commonly found in the interstitial space, is overexpressed and deposited in the stroma by PDAC cells (50).

In vitro assays using α1(IV)-siRNA demonstrated that collagen IV silencing reduces tumor cell proliferation and migration and increases apoptosis (51). Lastly, the fibrillar collagen, collagen V, is often identified as PSC-derived in PDAC and can be blocked by inhibiting β1-integrin signaling. Genetic knock-down of collagen V in orthotopic mouse models demonstrated reduced tumor metastasis and angiogenesis (52).

Collagen Signaling
ECM collagens interact with signaling integrins expressed on the surface of PDAC cells. Collagens bind with the α- and β-subunits of integrins depending on the integrin specificity of the collagen subtype (53). Interstitial collagens I, IV, and V have a high affinity for integrin α2β1, and the interaction between collagen I or V with α2β1 promotes proliferation and migration of PDAC cells (51, 52, 54–56). Like integrin-mediated signaling, collagens also interact with the cell surface receptor discoidin receptor 1 (DDR-1), a tyrosine kinase overexpressed by PDAC cells. Active DDR-1 activates FAK-related protein tyrosine kinase (PYK2) (57).

Collagen as Nutrients
Proliferating tumor cells require a constant supply of nutrients which are scarcely present in the dense desmoplastic tissue. Furthermore, the TME is generally hypoxic due to increased intra-tumoral oncotic pressure that decreases tissue perfusion. To adapt, PDAC cells may use large macropinosomes to non-specifically take up nutrients from the surrounding TME in bulk (58–60). In this way, PDAC cells are thought to actively scavenge the TME’s breakdown products and use collagen-derived proline as a primary source of energy in the absence of glucose (61, 62) (Figure 1). Likewise, proline oxidase (PRODH1) is overexpressed in proline catabolizing PDAC cells (62).

INTEGRINS, PROTEOGLYCANS, AND GLYCOPROTEINS
In addition to collagen, the TME also contains integrins, proteoglycans, and glycoproteins. Integrins mediate the interactions between TME cell-types and ECM proteins like proteoglycans and glycoproteins. Both proteoglycans and glycoproteins undergo post-translational glycosylation which modulates their functions and conformation. Aberrant glycosylation, a hallmark of several cancers, modifies the behavior of proteoglycans and glycoproteins in the TME; therefore, it is expected that the two classes of proteins play several modified roles in the TME (63).

Integrins
Integrins are transmembrane cell-surface receptors that heterodimerize upon binding ECM glycoproteins like fibronectin (FN1) and vitronectin (VN), collagens, and laminin (64). These cell-surface receptors are the major cell-adhesion receptors that interact with the ECM. In addition to directly

FIGURE 1 | The dichotomous role of the stroma and common interactions between PDAC tumor cells, the ECM, and CAFs. The stroma’s ECM plays both a tumor promoting role (left) and a tumor suppressive role (right). Tumor promoting roles may include integrin, TGFβ/SMAD, and DDR-1 signaling, as well as providing nutrition via collagen fragments. Tumor suppressive roles may include providing a barrier to metastases and increasing immune response. The ECM (middle) is deposited by CAFs and modulated by MMP, LOX, TG2, HA, and others, CAF, cancer associated fibroblasts; TGF- beta, transforming growth factor beta; HA, hyaluronan; FN-1, fibronectin 1; VN, vitronectin; DDR-1, discoidin receptor 1; PYK2, FAK-related protein tyrosine kinase; FAK, focal adhesion kinase; TG2, tissue transglutamase; LOX, lysyl oxidase.
contacting the ECM, activated integrins recruit the adhesome to the cytosolic tail of the integrin, a complex assortment of signaling, scaffolding, and cytoskeletal proteins (65–67). Differentially expressed in several solid tumors including PDAC, integrin roles are multi-faceted and participate in the metastatic cascade (68–70). Integrin-to-ECM contact points serve as molecular clutches to propel tumor cells forward by converting actin-polymerization into traction force (71, 72). In addition, by promoting the expression of matrix metalloproteinases (MMPs), integrins increase the proteolytic activity within the ECM and may facilitate the release of individual cancer cells or cell clusters from the TME (73). Integrin expression on cancer cells and endothelial cells has also been implicated in extravasation (74). In particular, PDAC zebrafish and mouse models demonstrated that the interaction between α5 integrin and neuropilin-2 facilitates the binding of cancer cells to the endothelium (75). Knockdown using lentiviral RNA-interference reduced cell adhesion, migration, and proliferation in vitro and vivo (76). In PDAC mouse models, the galectin-3 (GAL3) interaction with αvβ3 integrin may serve as an underlying mechanism of KRAS addiction and increase nutrient uptake via micropinocytosis (77). Altogether, PDAC has demonstrated overexpression of members of the integrin family like β1, β3, and β6 compared to normal pancreas (64, 69).

Glycoproteins and Proteoglycans
The glycoprotein galectin-1 (GAL1) has been found to be upregulated in the PDAC TME, alongside other glycoproteins like peristatin and fibulin and is in low-expressed in long-lived (≥10 years) survivors of PDAC (78–80). Loss of GAL1 in murine models leads to reduced stromal activation and increased cytotoxic T-cell infiltration (81). FN1 and VN are thought to serve as scaffolding proteins in the PDAC TME and regulate cellular processes (82, 83). FN1 enables tumor cells to infiltrate the basement membrane, stimulates their proliferation, and bridges the interactions between ECM collagens and integrins (84–86) (Figure 1). FN1 is also known to stimulate transforming growth factor-β (TGFβ) secretion, in turn promoting the activation of the stroma (87). Secreted protein acidic and rich in cysteine (SPARC) is another major glycoprotein in the PDAC stroma that modulates ECM organization by directly binding to collagens I, III, IV, and V (88, 89). In addition, SPARC, expressed in the stroma from fibroblasts, regulates the interactions between integrins and ECM proteins by binding α5β1 focal adhesion sites (90). SPARC deficient mice demonstrated reduced collagen fibrillogenesis, and elevated metastasis (88).

The glycoprotein subclass, proteoglycans, often modulate the hydration level of the interstitial fluid, and in turn interstitial pressure, through its interactions with hyaluronic acid (HA) (91). However, HA modulation of interstitial pressure is suggested to be dependent on the collagen-richness of the TME and may not occur in collagen-replete TMEs (92). The TME of PDAC overproduces an abundance of HA beginning at the pre-malignant intraepithelial neoplasia (PanIN) stage (17). When HA is enzymatically depleted in mouse models, the delivery of cytotoxic therapies is enhanced, likely due to a compromised ECM lacking HA (17, 93).

Secretome Studies
PDAC secretome analyses aim to examine the surrounding PDAC environment to identify aberrant proteins or molecules that may be influence tumor progression. A meta-analysis of 20 PDAC secretome studies from cell lines and patient tissues found that proteins associated with extracellular exosomes, blood microparticles, membrane-bound, secretory lumen and cytoplasmic membrane-bound vesicles, were most commonly found (94). Notable proteins found among the secretome and proteome across 20 secretome studies and 35 proteome studies include TGFβ induced (TGFBI), vimentin, and fibronectin (94). Using 3D organotypic cell cultures, Biondani et al. demonstrated that incubating cells with increasing type I collagen promoted the secretion of pro-angiogenic and growth factors like epidermal growth factor (EGF), matrix metalloproteinase 9 (MMP9), and vascular endothelial growth factor (VEGF) (95).

REGULATION OF THE ECM
PSCs are thought to maintain the balance between ECM synthesis and degradation and serve as a cellular reservoir for vitamin A and lipids (96). In the presence of tumor cells, PSCs assume an “activated” state in which they excessively deposit ECM proteins; become elongated in shape; and demonstrate increased expression of αSMA, collagens, immune-modulating, and other tumor-promoting genes (96). The formation of CAFs from PSCs is thought to be mediated by the PDAC secretome, which is abundant in fibroblast growth factor 2 (FGF2), TGFβ, and the paracrine and autocrine signaling regulator, sonic hedgehog (Shh) (97, 98). Shh functions to attract and activate PSCs, as PSCs demonstrate enhanced migration towards Shh overexpressing PDAC cells (98, 99). PSC activation through paracrine signaling has been shown to be inhibited with metformin, an activator of AMP-activated protein kinase (AMPK) (100).

TGFβ may suppress tumor growth in the early stages of carcinogenesis by inhibiting the proliferation of epithelial cells (101). However, in late stages of carcinogenesis, TGFβ promotes ECM deposition and tumor progression (101). A potent activator of PSCs, TGFβ mediates the interaction between the TME and tumor cells by binding TGFβ cell surface receptors. In PDAC, TGFβ promotes the deposition of several ECM proteins including fibronectin and collagens (102). On the surface of tumor cells, TGFβ receptor bind TGFβ to regulate downstream Smad-mediated gene transcription (103). PDAC-secreted TGFβ1 and FGF2 then promote ECM deposition by PSCs, as well as a positive feedback loop whereby PSCs secrete additional TGFβ1 that bind to TGFβ1 receptors found on the surface of PSCs. Once activated, PSCs, also known as CAFs, further modulate the ECM through a variety of mechanisms.

Tissue stiffness has been shown to enhance tumor cell proliferation in models of breast cancer (104). Stiff ECM matrices modulate vimentin, E-cadherin (CDH1), and ECM
MMP activity (105, 106). Stiffening of the stroma is enhanced by collagen cross-linking carried out by LOX and tissue transglutaminase 2 (TG2) (107, 108) (Figure 1). LOX expression is increased under hypoxic conditions and systematic neutralization of LOX results in reduced proliferation and improved survival in mouse models (13, 107). On the other hand, TG2 secreted into the ECM promotes collagen I cross-linking and stimulates CAFs to produce additional collagen I (108, 109). In pancreatic tissue, TG2 is mildly expressed unless malignancy is present (108). Similar to stiffness, increased collagen fiber thickness is associated with poor patient outcome (110). The additional cross-linked collagen fi stiness, increased collagen in response to mechanical stiffness (111 cues, highlighted by increased nuclear localization of YAP/TAZ is the central hub for the cellular response to external mechanical proliferation (105). It is suggested that the YAP/TAZ signaling with a PDZ-binding motif (TAZ) that enhances cell associated protein (YAP) and the transcriptional coactivator and stiff ECM, prompted by TG2 and/or LOX, activates yes-

| NCT registry number | Agent | Targets | Study population | Phase | Recruitment status |
|---------------------|-------|---------|-----------------|-------|--------------------|
| NCT01959139         | PEGPH20 + modified FOLFIRINOX | HA + chemotherapy | Metastatic PDAC | I/II | Active, not recruiting |
| NCT02715804         | PEGPH20 + nab-Paclitaxel + Gemcitabine | HA + chemotherapy | Hyaluronan-high Stage IV untreated PDAC | III | Terminated (sponsor decision) |
| NCT01195415         | Vismodegib + Gemcitabine | Shh pathway + chemotherapy | Advance PDAC | II | Completed |
| NCT01088815         | Vismodegib + Gemcitabine + nab-Paclitaxel | Shh pathway + chemotherapy | Metastatic PDAC | II | Completed |
| NCT01064622         | Vismodegib + Gemcitabine | Shh pathway + chemotherapy | Recurrent or metastatic PDAC | II/II | Completed |
| NCT01383538         | IFI-926 + FOLFIRINOX | Muti-AOC kinases including ROCK-AKT | Advance PDAC | I | Completed |
| NCT01585701         | AT13148 | HA + chemotherapy | Advance solid tumors | I | Completed |
| NCT03519308         | Paricalcitol + Nivolumab + nab-Paclitaxel + Gemcitabine | Vitamin D Receptor + PD-L1 + chemotherapy | Resectable PDAC | I | Recruiting |
| NCT04617067         | Paricalcitol + Gemcitabine + nab-Paclitaxel | Vitamin D Receptor + chemotherapy | Advance PDAC | II | Recruiting |
| NCT04524702         | Paricalcitol + Hydroxychloroquine + Gemcitabine + nab-Paclitaxel | Vitamin D Receptor + autophagy + chemotherapy | Advance or metastatic PDAC | II | Recruiting |
| NCT03331562         | Paricalcitol + Pembrolizumab | Vitamin D Receptor + PD-1 | PDAC (maintenance) | II | Completed |
| NCT02930902         | Paricalcitol + Pembrolizumab + Gemcitabine + nab-Paclitaxel | Vitamin D Receptor + PD-1 + chemotherapy | Resectable PDAC | I | Active, not recruiting |
| NCT02030860         | Paricalcitol + nab-Paclitaxel + Gemcitabine | Vitamin D Receptor + chemotherapy | Resectable PDAC | NA | Completed |
| NCT03138720         | Paricalcitol + nab-Paclitaxel + Gemcitabine + Cisplatin | Vitamin D Receptor + chemotherapy | Advance PDAC | II | Active, not recruiting |
| NCT03415854         | Paricalcitol + nab-Paclitaxel + Gemcitabine + Cisplatin | Vitamin D Receptor | Metastatic PDAC | II | Active, not recruiting |
| NCT02754726         | Paricalcitol + Nivolumab + nab-Paclitaxel + Gemcitabine + Cisplatin | Vitamin D Receptor + PD-L1 + chemotherapy | Active, not recruiting | | |
| NCT01646203         | LY3022859 | TβRIi | Advance solid tumors | I | Completed |
| NCT00557856         | PF-03446962 | TβRIi | Advance solid tumors | I | Completed |
| NCT04296942         | Bintrafusp alfa | TβRIi + PD-L1 | Advance solid tumors | I | Completed |
| NCT01682187         | Galunisertib | TβRIi | Advance solid tumors | I | Completed |
| NCT01373164         | Galunisertib + Gemcitabine | TβRIi + chemotherapy | Inoperable or metastatic PDAC | I/II | Completed |
| NCT02154646         | Galunisertib + Gemcitabine | TβRIi + chemotherapy | Inoperable or metastatic PDAC | I | Completed |
| NCT02734166         | Galunisertib + Durvalumab | TβRIi + PD-L1 | Metastatic PDAC | I | Completed |
| NCT03192345         | SAR438459 + Cemiplimab | Tgifβ1, Tgifβ2, and Tgifβ1 + PD-L1 | Advance solid tumors | I | Active, recruiting |

**TARGETING THE ECM**

**Hyaluronic Acid**

The rationale for targeting the ECM as an adjunct to chemotherapy in PDAC relies on our understanding of the roles that ECM plays in promoting tumorigenesis. Early studies in mouse models showed that tumors with a high HA content had increased interstitial pressure that resulted in vascular collapse and diminished tumor perfusion. Treating these mice with a hyaluronidase inhibitor reversed these effects, creating an amenable environment for intra-tumoral drug delivery (17, 114). Since HA contributed to intra-tumoral pressure which in-turn affected drug delivery, the hypothesis was that targeting HA would improve drug delivery and efficacy. In SWOG S1313 (NCT01959139), PEGPH20 was evaluated in combination with mFOLFIRINOX and in the HALO trial (NCT02715804), in combination with nab-paclitaxel plus gemcitabine (Table 1) (19, 115). Unfortunately, some patients experienced strong adverse reactions to PEGPH20 and those who tolerated it did not have an improvement in overall survival (115).
Hedgehog Pathway

Treating mice with Shh inhibitors in addition to chemotherapy improved tumor microvascular density and survival (9). The addition of Shh inhibitors to either FOLFIRINOX or gemcitabine in clinical trials failed to improve overall survival and, in some cases, was associated with a worse outcome (Table 1) (20, 30). These studies were done prior to our understanding of CAF heterogeneity, and recent work has been done to further elucidate the underlying biology responsible for the discrepancy in clinical findings. Recent studies suggest that blocking the Shh signaling pathway may shift the stroma CAF populations from myofibroblast-CAFs (myCAFs) to inflammatory CAFs (iCAFs) and promote an immunosuppressive TME (116).

Rho Kinase Inhibitors

Rho kinase (ROCK) inhibitors alter PDAC cell cytoskeletal contractility and CAF contractility and may enable more favorable drug delivery in PDAC as well as inhibit PDAC metastasis. ROCK inhibition resulted in a disorganized ECM that blunted PDAC migration and invasion in vitro. In vivo models including both subcutaneous and intrasplenic injection found that administering ROCK-inhibitors prior to chemotherapy resulted in increased primary tumor response to chemotherapy and helped prevent the growth and establishment of liver metastases (117–120). A phase 1 study using a kinase inhibitor, AT13148, with anti-ROCK/II activity was carried out in patients with metastatic solid tumors, but did not proceed further due to toxicity (Table 1) (121).

Vitamin D

Vitamin D halts the secretion of collagen in several cell types, possibly by disrupting TGF-β signaling (103, 122). The vitamin D receptor (VDR) has been shown to regulate transcription of PSCs and CAFs (123, 124). Treatment with VDR ligand, calcipotriol, reprograms the stroma, decreases inflammation and improves response to gemcitabine (123). Other studies have shown that while calcipotriol decreases CAF migration and inflammation, it also may negatively affect T cell effector functions (125, 126). Several studies of paricalcitol, a vitamin D analogue, in combination with chemotherapies and immunotherapies are ongoing (Table 1).

TGFβ

Preclinical experimental data has suggested that blocking TGFβ-mediated signaling likely enhances antitumor effects in solid tumors. Further, PDAC is often characterized by high TGFβ expression levels (101). Several clinical trials have attempted to target TGFβ in a variety of cancers, but no TGFβ-targeting inhibitor has been approved for use (127). There is currently at least one ongoing clinical trial targeting TGFβ in PDAC (Table 1) that is investigating the pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR439459 alone and in combination with cemiplimab. SAR439459 is a pan-TGFβ neutralizing antibody that targets the three TGFβ isoforms (TGFβ1, 2 and 3) and their interaction with type II TGFβ cell surface receptors (128).

CONCLUDING REMARKS

The ECM plays an important role in PDAC tumor growth, metastasis, and therapy resistance. Accumulating preclinical studies with patient-derived specimens indicate that targeting the dense desmoplastic ECM proteins of PDAC may provide promising clinically useful therapies. In clinical practice, we have yet to successfully target the ECM in a way that improves overall survival. The clinical shortcomings of once promising therapies are a humble reminder of the underlying complexity of tumor biology. Learning from these failures and developing a deeper understanding of the fundamental biology allows researchers to identify further vulnerabilities that should be considered when developing treatments. Tumor and CAF subtypes have been identified that were previously not known and will likely improve the outcome of ECM modulating studies if performed using reproducible subtyping methods and tailored targeting techniques (15, 16, 129–133). Recent advances foster hope that ECM-modulating therapies are likely to become a crucial part of the toolkit for oncologists in the next few decades.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial direct and intellectual contribution to the work and approved it for publication.

FUNDING

This work was financially supported by the National Cancer Institute of the National Institutes of Health under the award numbers R01-CA199064 (JY) and T32-CA244125 (JK, VP).

ACKNOWLEDGMENTS

Figures for this publication were created with BioRender.com.

REFERENCES

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res (2014) 74:2913. doi: 10.1158/0008-5472.CAN-14-0155
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer J Clin (2021) 71:7–33. doi: 10.3322/caac.21654
3. Bulaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2016) 34:2654–68. doi: 10.1200/JCO.2016.67.3561
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer. New Engl J Med (2011) 364:1817–25. doi: 10.1056/NEJMoa1011923
5. Von Hoff DD, Ervin T, Arena FP, Chioroan EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine. *New Engl J Med* (2013) 369:1691–703. doi: 10.1056/NEJMoa1304369
6. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *New Engl J Med* (2019) 381:317–27. doi: 10.1056/NEJMoa1903387
7. Pandol S, Edderkoussi M, Gukovskiy I, Luga D, Gukovskaya A. Desmoplasia of Pancreatic Ductal Adenocarcinoma. *Clin Gastroenterol Hepatol* (2009) 7: S44–7. doi: 10.1016/j.cgh.2009.07.039
8. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan Impairs Vascular Function and Drug Delivery in a Mouse Model of Pancreatic Cancer. *Gut* (2013) 62:112–20. doi: 10.1136/gutjn-2012-302529
9. Orave KJ, Jacobetz MA, Davidson CJ, Gopinathan A, Mcintyre D, Honess D, et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. *Science* (2009) 324:1457–61. doi: 10.1126/science.1171362
10. Elahi-Gedwillo KY, Carlson M, Zettervall J, Provenzano PP. Anti-Tumor Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. *Cancer Res* (2019) 79:372–86. doi: 10.1158/0008-5472.CAN-18-1333
11. Lee JJ, Perera RM, Wang H, Wu D-C, Liu XS, Han S, et al. Stromal Response to Hedgehog Signaling Restrains Pancreatic Cancer Progression. *Proc Natl Acad Sci USA* (2014) 111:E3091–100. doi: 10.1073/pnas.1411679111
12. Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, Delgjorno KE, et al. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. *Cell* (2015) 161:1345–60. doi: 10.1016/j.cell.2015.04.028
13. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, et al. Combination With Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. *J Cancer Res Clin Oncol* (2015) 33:4284–92. doi: 10.1200/JCO.2015.62.8719
14. Neese A, Bauer CA, Oehlund D, Lauth M, Buchholz M, Michał P, et al. Stromal Biology and Therapy in Pancreatic Cancer: Ready for Clinical Translation? *Gut* (2019) 68:159. doi: 10.1136/gutjnl-2018-316451
15. Humphrey JD, Dufresne ER, Schwartz MA. Mechanotransduction and Extracellular Matrix Homeostasis. *Nat Rev Mol Cell Biol* (2015) 16:802–12. doi: 10.1038/nrmm.896
16. Provenzano PP, Clive SH, Goel VK, Von Hoff DD, Hingorani KD, et al. The Good and the Bad Collagens of Fibrosis. *Proc Natl Acad Sci USA* (2014) 111:E3091. doi: 10.1073/pnas.1411679111
17. Provenzano PP, Barlow KA, Greenson JK, Takebe N, et al. Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Untreated Metastatic Pancreatic Adenocarcinoma. *Br J Cancer* (2019) 122:498–505. doi: 10.1038/s41416-019-0683-3
18. Özdemir BC, Pentcheva-Hoang T, Rickelt S, Huang Y, Gupta M, et al. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. *Cell* (2019) 178:160–175.e127. doi: 10.1016/j.cell.2019.05.012
19. Xu Q, Wang Z, Chen X, Duan W, Lei J, Zong L, et al. Stromal-Derived Factor-1α/CXCL12-CXCR4 Chemotactic Pathway Promotes Perineural Invasion in Pancreatic Cancer. *Oncotarget* (2015) 6:4717–32. doi: 10.18632/oncotarget.3069
20. Wu ZX, Chen D, Xie GR. Extracellular Matrix Remodeling in Hepatocellular Carcinoma: Effects of Soil on Seed? *Mol Hypotheses* (2006) 66:1115–20. doi: 10.1016/j.mehy.2005.12.043
21. Parker AL, Cox TR. The Role of the ECM in Lung Cancer Dormancy and Outgrowth. *Front Oncol* (2020) 10:1766–6. doi: 10.3389/fonc.2020.01766
22. Ko AH, Loconte N, Tempero MA, Walker EJ, Katekel R, Lewis S, et al. A Phase I Study of FOLFIRINOX Plus IPI-946, A Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. *Pancreas* (2016) 45:370–5. doi: 10.1097/MPA.0000000000000458
23. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. *Cancer Cell* (2014) 25:735–47. doi: 10.1016/j.ccr.2014.04.021
24. Tian C, Clauser KR, Oehlund D, Rickelt S, Huang Y, Gupta M, et al. Proteinogenic Analyses of ECM During Pancreatic Ductal Adenocarcinoma Progression Reveal Different Contributions by Tumor and Stromal Cells. *Proc Natl Acad Sci USA* (2019) 116:19609–18. doi: 10.1073/pnas.1908626116
25. Weniger M, Honsellmann KC, Liss AS. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. *Cancers* (2018) 10:316. doi: 10.3390/cancers10093016
26. Van Agtmael T, Bruckner-Tuderman L. Basement Membranes and Human Disease. *J Exp Med* (2013) 214:579–96. doi: 10.1084/jem.20122024
27. Provenzano PP, Cuebas C, Chang AE, Goel VK, Von Hoff DD, Hingorani KD. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. *Cancer Cell* (2012) 21:418–29. doi: 10.1016/j.ccr.2012.01.007
28. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu C-C, Simpson TR, et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer With Reduced Survival. *Cancer Cell* (2014) 25:719–34. doi: 10.1016/j.ccr.2014.04.005
29. Ramanathan RK, Mcdownough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, et al. Phase Ib/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. *J Clin Oncol* (2019) 37:1062–9. doi: 10.1200/JCO.18.01295
30. Kim EJ, Sahai V, Abel EY, Griffith KA, Greenson JK, Takebe N, et al. Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma. *Clin Cancer Res* (2014) 20:5937–45. doi: 10.1158/1078-0432.CCR-14-1269
31. De Jesus-Acosta A, Sugar EA, O’dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z, et al. Phase 2 Study of Vismodegib, a Hedgehog Inhibitor, Combined With Gemcitabine and Nab-Paclitaxel in Patients With Untreated Metastatic Pancreatic Adenocarcinoma. *Br J Cancer* (2020) 122:498–505. doi: 10.1038/s41416-019-0683-3
of Drug Resistance Development. *Int J Mol Sci* (2018) 20:54. doi: 10.3390/ijms2010054

41. Jakubzík B, Baltes F, Henze S, Schliesinger M, Bendas G. Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells-Deciphering Novel Potential Targets for a Cell Sensitization. *Cancers* (2018) 10:495. doi: 10.3390/cancers10120495

42. Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang YA, Lucas FAS, et al. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. *Clin Cancer Res* (2018) 24:5883–94. doi: 10.1158/1078-0432.CCR-17-3668

43. Immamura T, Iuchi H, Manabe T, Ohshio G, Yoshimura T, Wang Z-H, et al. Quantitative Analysis of Collagen and Collagen Subtypes I, III, and V in Human Pancreatic Cancer, Tumor-Associated Chronic Pancreatitis, and Alcoholic Chronic Pancreatitis. *Pancreas* (1995) 11:357–64. doi: 10.1097/00006667-199511000-00007

44. Mollenhauer J, Roether I, Kern HF. Distribution of Extracellular Matrix Proteins in Pancreatic Ductal Adenocarcinoma and Its Influence on Tumor Cell Proliferation *In Vitro. Pancreas* (1987) 2:14–24. doi: 10.1097/00006667-198701000-00003

45. Whatcott CJ, Diep CH, Jiang P, Watanabe A, Lobello J, Sima C, et al. Collagen Fragments Quantitatively Activate the VEGF165–206 System in Pancreatic Cancer. *Cancer Res* (2015) 75:544–53. doi: 10.1158/0008-5472.CAN-14-2211

46. Olivares O, Mayers JR, Gourard V, Torrence ME, Gicquel T, Borge L, et al. Collagen-Derived Proline Promotes Pancreatic Ductal Adenocarcinoma Cell Survival Under Nutrient Limited Conditions. *Nat Commun* (2017) 8:16031. doi: 10.1038/ncomms16031

47. Carstens JL, Correa De Sampaio P, Yang D, Barua S, Wang H, Rao A, et al. Collagens Produced Selectively by Tumor Cells. *Nat Commun* (2015) 6:5962. doi: 10.1038/ncomms13257

48. Madsen CD. Pancreatic Cancer Is Suppressed by Fibroblast-Derived Collagen I. *Cancer Cell* (2021) 39:451–3. doi: 10.1016/j.ccell.2021.02.017

49. Ohlund D, Lundin C, Ardnor B, Oman M, Naredi P, Sund M. Type IV Collagen Is a Tumour Stroma-Derived Biomarker for Pancreas Cancer. *World J Gastroenterol* (2016) 22:9288–99. doi: 10.3748/wjg.v22.i42.9288

50. Madsen CD. Pancreatic Cancer Is Suppressed by Fibroblast-Derived Collagen I. *Cancer Cell* (2021) 39:451–3. doi: 10.1016/j.ccell.2021.02.017

51. Ruggiero F, Comte J, Bégañas C, Garrone R. Structural Requirements for Alpha 1 Beta 1 and Alpha 2 Beta 1 Integrin Mediated Cell Adhesion to Collagen V. *J Cell Sci* (1996) 109(Pt 7):1865–74. doi: 10.1242/jcs.109.7.1865

52. Valitutti RR, Marco M, Leitinger B, Klee CG, Fridman R, Discisdom Domain Receptor Tyrosine Kinases: New Players in Cancer Progression. *Cancer metastasis rev* (2012) 31:295–321. doi: 10.1007/s10555-012-9346-z

53. Commissio C, Davidson SM, Sydnoymer-Axelglo SG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of Protein Is an Amino Acid Supply Route in Ras-Transformed Cells. *Nature* (2013) 497:633–7. doi: 10.1038/nature12138

54. Arri-Sagi D, Feramisco JR. Induction of Membrane Ruffling and Fluid-Phase Pinocytosis in Quiescent Fibroblasts by Ras Proteins. *Science* (1986) 233:1061. doi: 10.1126/science.3090687

55. Ambruosio J, Shi R, Sprague S, Oliver M, Patrone A, Willumsen N, et al. Direct Evidence for Cancer-Cell-Autonomous Extracellular Protein Catabolism in Pancreatic Tumors. *Nat Med* (2017) 23:235–41. doi: 10.1038/nm.4256

56. Perez et al. The PDAC Extracellular Matrix Proteome 2021 - 8
Perez et al. The PDAC Extracellular Matrix Proteome

93. Thompson CB, Shepard HM, Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Suppression by Metformin-Mediated AMPK Activation Induces Pantetrazine Cancer Cells. Cancer Lett (2017) 385:225–33. doi: 10.1016/canlet.2016.10.019

94. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, et al. Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer. Clin Cancer Res (2008) 14:5995–6004. doi: 10.1158/1078-0432.CCR-08-0291

95. Di Biase MV, Pirola RC, Wilson JS. Pancreatic Stellate Cells: A Starring Role in Normal and Diseased Pancreas. Front Physiol (2012) 3:344. doi: 10.3389/fphys.2012.00344

96. Bachem MG, Schneider E, Groß H, Weidenbach H, Schmid RM, Menke A, et al. Identification, Culture, and Characterization of Pancreatic Stellate Cells in Rats and Humans. Gastroenterology (1998) 115:421–32. doi: 10.1016/S0016-5085(98)70209-4

97. Nien J, Chang B, Traktuev DO, Sun J, March K, Chan L, et al. IFATS Annual Meeting: Combinatorial Peptide Selection: Alpha5beta1 Integrin as a Receptor for the Matricellular Protein SPARC on Adipose Stromal Cells. (Dayton Ohio) (2013) 7:39. doi: 10.1038/jcb.2013.00006

98. Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, et al. Lack of Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Perineural Invasion in Pancreatic Cancer. Cancer Lett (2014) 385:225–33. doi: 10.1016/canlet.2016.10.019

99. Kato Y, Inoue H, Yoshioka U, Fujiyama Y, Bamba T. Effects of Transforming Growth Factor-α1, Interleukin-1β, Tumor Necrosis Factor α and Platelet-Derived Growth Factor on the Collagen Synthesis and the Proliferation of Periaccial Fibroblast Cells Isolated and Cultured From Rat Pancreatic Acini. Pathophysiology (1996) 3:175–9. doi: 10.1016/0928-4680(96)00012-0

100. Shany S, Sigal-Batikoff INA, Lamprecht S. Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-Purposes With TGF-β/SMAD Signaling. Anticancer Res (2016) 36:6225. doi: 10.21873/anticancer.11216

101. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rosenberg GI, Gfen A, et al. Tensional Homeostasis and the Malignant Phenotype. Cancer Cell (2005) 8:241–54. doi: 10.1016/cancer.2005.08.010

102. Rice AJ, Cortes E, Lachowski D, Cheung BCH, Karim SA, Morton JP, et al. Matrix Stiffness Induces Epithelial-Mesenchymal Transition and Promotes Chemoresistance in Pancreatic Cancer Cells. Oncogenesis (2017) 6:e352–2. doi: 10.1038/oncsis.2017.54

103. Haage A, Schneider IC. Cellular Contractility and Extracellular Matrix Stiffness Regulate Matrix Metalloproteinase Activity in Pancreatic Cancer Cells. FASEB J (2014) 28:389–99. doi: 10.1096/fj.13-245613

104. Cox TR, Bird D, Baker A-M, Barker HE, Ho MWY, Lang G, et al. LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced Metastasis. Cancer Res (2013) 73:1721–32. doi: 10.1158/0008-5472.CAN-12-2233

105. Lee J, Cordello S, Yakubov B, Emerson R, Capereill-Grant A, Hintomi K, et al. Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression. Clin Cancer Res (2015) 21:4842–93. doi: 10.1158/1078-0432.CCR-15-0226

106. Verderio EAM, Johnson T, Griffin M. Tissue Transglutaminase in Normal and Abnormal Wound Healing: Review Article. Amino Acids (2004) 26:387–404. doi: 10.1007/s00726-004-0094-4

107. Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, et al. Genotype Tunes Pancreatic Ductal Adenocarcinoma Tissue Tension to Induce Matrixcellular Fibrosis and Tumor Progression. Nat Med (2016) 22:497–505. doi: 10.1038/nm.4082

108. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in Mechanotransduction. Nature (2011) 474:479–83. doi: 10.1038/nature10137

109. Piccolo S, Dupont S, Cordenonsi M. The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiol Rev (2014) 94:1287–312. doi: 10.1152/physrev.00005.2014

110. Gruber R, Panayiotou R, Nye E, Spencer-Dene B, Stamp G, Behrens A. YAP and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-Regulation of JAK-STAT3 Signaling. Gastroenterology (2016) 151:526–39. doi: 10.1053/j.gastro.2016.05.006
114. Li X, Shepard HM, Cowell JA, Zhao C, Osgood RJ, Rosengren S, et al. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clin Cancer Res (2018) 24:4798–807. doi: 10.1158/1078-0432.CCR-17-3284

115. Van Cutsem E, Tempero MA, Sigal D, Oh D-Y, Fazio N, Macarulla T, et al. Randomized Phase III Trial of Pevorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol (2020) 38:3185–94. doi: 10.1200/JCO.20.00590

116. Steele NG, Biffi G, Kemp SB, Zhang Y, Drouillard L, Syu L, et al. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Clin Cancer Res (2021) 27:2023. doi: 10.1158/1078-0432.CCR-20-3715

117. Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, et al. Transient Tissue Priming via ROCK Inhibition Uncouples Pancreatic Cancer Progression, Sensitivity to Chemotherapy, and Metastasis. Sci Transl Med (2017) 9:eaa8504. doi: 10.1126/scitranslmed.aai8504

118. Rath N, Munro J, Cuticchia MF, Jagiello A, Gadegaard N, McGarry L, et al. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. Cancer Res (2018) 78:3321–36. doi: 10.1158/0008-5472.CAN-17-1339

119. Whatcott CJ, Ng S, Barrett MT, Hostetter G, Von Hoff DD, Han H. Inhibition of ROCK1 Kinase Modulates Both Tumor Cells and Stromal Fibroblasts in Pancreatic Cancer. PLoS One (2017) 12:e0183871–e0183871. doi: 10.1371/journal.pone.0183871

120. Vennin C, Rath N, Pajic M, Olsson MF, Timpson P. Targeting ROCK Activity to Disrupt and Prime Pancreatic Cancer for Chemotherapy. Small GTPases (2020) 11:45–52. doi: 10.1080/21541248.2017.1345712

121. Mcleod R, Kumar R, Papadatos-Pastos D, Mateo J, Brown JS, Garces AH, et al. First-In-Human Study of AT13148, a Dual ROCK-akt Inhibitor in Patients With Solid Tumors. Clin Cancer Res (2020) 26:6777. doi: 10.1158/1078-0432.CCR-20-0700

122. Artaza IN, Norris KC. Vitamin D Reduces the Expression of Collagen and Key Profibrotic Factors by Inducing an Antifibrotic Phenotype in Mesenchymal Multipotent Cells. J Endocrinol (2009) 200:207–21. doi: 10.1677/JOE-08-0241

123. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell (2014) 159:80–93. doi: 10.1016/j.cell.2014.08.007

124. Porter RL, Magnus NKC, Thapar V, Morris R, Szabolcs A, Neyaz A, et al. Epithelial to Mesenchymal Plasticity and Differential Response to Therapies in Pancreatic Ductal Adenocarcinoma. Proc Natl Acad Sci (2019) 116:26835. doi: 10.1073/pnas.1914915116

125. Cheng H, Lu C, Tang R, Pan Y, Bao S, Qiu Y, et al. Ellagic Acid Inhibits the Proliferation of Human Pancreatic Carcinoma PANC-1 Cells In Vitro and In Vivo. Oncotarget (2017) 8:12301–10. doi: 10.18632/oncotarget.14811

126. Gorchs L, Ahmed S, Mayer C, Knauf A, Fernández Moro C, Svensson M, et al. The Vitamin D Analogue Calcipotriol Promotes an Anti-Tumorigenic Phenotype of Human Pancreatic CAFs But Reduces T Cell Mediated Immunity. Sci Rep (2020) 10:17444. doi: 10.1038/s41598-020-74368-3

127. Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical Development of Therapies Targeting Tgfβ: Current Knowledge and Future Perspectives. Ann Oncol (2020) 31:1336–49. doi: 10.1016/j.annonc.2020.07.009

128. Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, et al. Pan-Tgfβ Inhibition by SAR439459 Relieves Immunosuppression and Improves Antitumor Efficacy of PD-1 Blockade. Oncoimmunology (2020) 9:1811605–1811605. doi: 10.1080/2162402X.2020.1811605

129. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, et al. Virtual Microdissection Identifies Distinct Tumor- and Stroma-Specific Subtypes of Pancreatic Ductal Adenocarcinoma. Nat Genet (2015) 47:1168–78. doi: 10.1038/ng.3398

130. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular Subtypes of Pancreatic Cancer. Nat Rev Gastroenterol Hepatol (2019) 16:207–20. doi: 10.1038/s41575-019-0109-y

131. Elyada E, Bolisetty M, Laise P, Flynn WF, Courtis ET, Burkha RT, et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discovery (2019) 9:1102–23. doi: 10.1158/2159-8290.CD-19-0094

132. Daemen A, Peterson D, Sahu N, Mccord R, Du X, Liu B, et al. Metabolite Profiling Stratifies Pancreatic Ductal Adenocarcinomas Into Subtypes With Distinct Sensitivities to Metabolic Inhibitors. Proc Natl Acad Sci (2015) 112: E4410. doi: 10.1073/pnas.1501605112

133. Ogawa Y, Masugi Y, Abe T, Yamazaki K, Ueno A, Fujii-Nishimura Y, et al. The Vitamin D Analogue Calcipotriol Promotes an Anti-Tumorigenic Program in Pancreatic Ductal Adenocarcinomas. Sci Rep (2020) 10:9411. doi: 10.1038/s41598-020-74386-9

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.